Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


31.05.2021

1 Acta Neurol Scand
2 Ann Neurol
1 Arch Phys Med Rehabil
1 Can J Neurol Sci
1 Curr Treat Options Neurol
1 Eur Neurol
1 J Neuroimmunol
2 J Neurol
1 J Neurol Sci
1 Lancet Neurol
8 Mult Scler
1 Nat Rev Neurol
6 Neurology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neurol Scand

  1. LANDTBLOM AM, Berntsson SG, Bostrom I, Iacobaeus E, et al
    Multiple sclerosis and COVID-19: The Swedish experience.
    Acta Neurol Scand. 2021 May 24. doi: 10.1111/ane.13453.
    PubMed         Abstract available


    Ann Neurol

  2. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    PubMed         Abstract available

  3. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed         Abstract available


    Arch Phys Med Rehabil

  4. KNOWLES LM, Phillips KM, Herring TE, Alschuler KN, et al
    Pain Intensity and Pain Interference in People with Progressive Multiple Sclerosis Compared to People with Relapsing-Remitting Multiple Sclerosis.
    Arch Phys Med Rehabil. 2021 May 25. pii: S0003-9993(21)00393.
    PubMed         Abstract available


    Can J Neurol Sci

  5. ROBERTS JI, Hahn C, Metz LM
    Multiple sclerosis clinic utilization is associated with fewer emergency department visits.
    Can J Neurol Sci. 2021 May 24:1-14. doi: 10.1017/cjn.2021.
    PubMed        


    Curr Treat Options Neurol

  6. SIMPSON A, Mowry EM, Newsome SD
    Early Aggressive Treatment Approaches for Multiple Sclerosis.
    Curr Treat Options Neurol. 2021;23:19.
    PubMed         Abstract available


    Eur Neurol

  7. SZILASIOVA J, Rosenberger J, Fedicova M, Mikula P, et al
    Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
    Eur Neurol. 2021 May 25:1-8. doi: 10.1159/000515806.
    PubMed         Abstract available


    J Neuroimmunol

  8. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed         Abstract available


    J Neurol

  9. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    PubMed         Abstract available

  10. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    PubMed         Abstract available


    J Neurol Sci

  11. TAZZA F, Lapucci C, Cellerino M, Boffa G, et al
    Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    J Neurol Sci. 2021;427:117501.
    PubMed         Abstract available


    Lancet Neurol

  12. MORGAN J
    Amit Bar-Or: breaking new ground in multiple sclerosis.
    Lancet Neurol. 2021;20:421.
    PubMed        


    Mult Scler

  13. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    PubMed        

  14. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    PubMed        

  15. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    PubMed        

  16. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed         Abstract available

  17. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed         Abstract available

  18. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed         Abstract available

  19. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed         Abstract available

  20. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed         Abstract available


    Nat Rev Neurol

  21. FOX RJ
    How common is active inflammation in progressive multiple sclerosis?
    Nat Rev Neurol. 2021 May 25. pii: 10.1038/s41582-021-00518.
    PubMed        


    Neurology

  22. FOX RJ, Kryscio RJ
    A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology. 2021;96:833-834.
    PubMed        

  23. KOCH MW, Sage K, Kaur S, Kim J, et al
    Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology. 2021;96:e2313-e2322.
    PubMed         Abstract available

  24. BAR-OR A, Herman A, Stokmaier D
    Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed        

  25. HAHN N
    Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed        

  26. SIEGLER JE, Galetta S
    Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:869.
    PubMed        

  27. TOOSY AT, Kapur K, Nair KV
    Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
    Neurology. 2021;96:927-928.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: